D.A. Davidson & CO. Has $29.67 Million Holdings in Stryker Co. (NYSE:SYK)

D.A. Davidson & CO. lifted its stake in shares of Stryker Co. (NYSE:SYK) by 0.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 82,123 shares of the medical technology company’s stock after purchasing an additional 405 shares during the period. D.A. Davidson & CO.’s holdings in Stryker were worth $29,668,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Mount Yale Investment Advisors LLC acquired a new position in Stryker during the 1st quarter worth $305,000. Bayesian Capital Management LP bought a new stake in shares of Stryker during the first quarter worth $895,000. Kennedy Capital Management LLC acquired a new position in shares of Stryker during the first quarter valued at $957,000. Tidal Investments LLC boosted its holdings in Stryker by 14.2% in the first quarter. Tidal Investments LLC now owns 13,558 shares of the medical technology company’s stock valued at $4,853,000 after acquiring an additional 1,681 shares during the last quarter. Finally, Coppell Advisory Solutions Corp. acquired a new stake in Stryker in the first quarter worth about $414,000. 77.09% of the stock is owned by institutional investors.

Insider Transactions at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,781 shares of company stock valued at $24,612,275 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SYK. BTIG Research raised their target price on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Robert W. Baird raised their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Wells Fargo & Company upped their target price on shares of Stryker from $381.00 to $405.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Stifel Nicolaus reduced their price target on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Finally, StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research note on Friday. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $393.65.

Stryker Trading Down 0.1 %

SYK opened at $384.63 on Tuesday. The firm’s fifty day simple moving average is $366.45 and its 200 day simple moving average is $350.00. The stock has a market capitalization of $146.63 billion, a P/E ratio of 41.23, a P/E/G ratio of 2.90 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12 month low of $285.79 and a 12 month high of $398.20.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the company earned $2.46 earnings per share. As a group, research analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.